Curriculum Vitae:

Head of the Hematology Department at Vall d’Hebron University Hospital, Head of the Hematology Department at IOB Institute of Oncology, Professor at Universitat Autònoma de Barcelona, Spain- Francesc Bosch holds the position of Head of the Hematology Department at Vall d’Hebron University Hospital, as well as Head of the Hematology Department at IOB Institute of Oncology. Additionally, he serves as a Professor at the Universitat Autònoma de Barcelona. Dr. Bosch earned his medical degree from the University of Barcelona Medical School in 1988. In 1997, he was awarded a PhD by the University of Barcelona for his research on the over-expression of Cyclin D1 in chronic lymphoproliferative disorders. He completed a two-year postdoctoral stay at the laboratory of Professor Riccardo Dalla Favera at the Institute of Cancer Genetics, Columbia University, New York, USA. Subsequently, he continued his research in chronic lymphocytic leukemia (CLL) at Hospital Clinic, Barcelona, starting from 2000. In September 2009, Dr. Bosch assumed the role of Head of the Department of Hematology and Director of the Experimental Hematology Laboratory at Vall d’Hebron University Hospital in Barcelona. Renowned for his expertise in CLL, Dr. Bosch conducts both clinical and basic research, focusing on the molecular pathogenesis of CLL and the development of innovative therapeutic strategies. Presently, Dr. Bosch serves as the Chair of the Spanish CLL Working Group (GELLC), overseeing the development of clinical trials related to CLL in Spain. He has published more than 200 papers in peer-reviewed journals such as The New England Journal of Medicine, Nature Medicine, Cancer Cell, Blood, Journal of Clinical Oncology, and Leukemia. Additionally, he has authored or co-authored numerous reviews and book chapters on CLL and other lymphoproliferative disorders

Curriculum Vitae:

Is a Professor of Medicine at the MD Anderson Cancer Center in Houston, USA. Dr. Burger received his M.D./Ph.D. degree at Albert-Ludwigs-University in Freiburg, Germany, with subsequent clinical training and board certification in Internal Medicine and Hematology/Oncology at Freiburg University Hospital, before moving to MD Anderson in 2005. In 2006, Dr. Burger received the “Venia legendi” (Habilitation) for Internal Medicine at Albert-Ludwigs-University in Freiburg. Moreover, from 1996 to 1999, Dr. Burger received postdoctoral research training in Hematology and Immunology at the University of California, San Diego. As a clinical and laboratory investigator, Dr. Burger focuses on developing new therapeutic approaches for targeting the microenvironment in chronic lymphocytic leukemia (CLL), other B cell malignancies, and acute leukemias. Laboratory research by Dr. Burger’s group characterized B cell receptor (BCR)-associated kinases, such as BTK and PI3 kinases, as therapeutic targets. Dr. Burger serves as a principal investigator on clinical trials which explore these targets in CLL, and has been leading key trials that supported the approval of the BTK inhibitor ibrutinib (Resonate 2: ibrutinib for CLL frontline therapy). For his innovative research, Dr. Burger received several awards, among them, the Arthur Pappenheim Award by the DGHO, a Kimmel Scholar Award, ASCO Young Investigator and Career Development awards, the Leukemia and Lymphoma Society Scholar award, and the MD Anderson Faculty Scholar Award. Dr. Burger is a regular speaker at EHA and ASH, and has published in the leading Journals in his field.